Syn2bio (WAR:S2B) Return-on-Tangible-Equity: -133.21% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio Return-on-Tangible-Equity?

Syn2bio WAR:S2B +1.88% 11 Return-on-Tangible-Equity is -133.21% as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Syn2bio ranks worse than 79.65% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Syn2bio's annualized net income for the quarter that ended in Sep. 2025 was zł-23.66 Mil. Syn2bio's average shareholder tangible equity for the quarter that ended in Sep. 2025 was zł17.76 Mil. Therefore, Syn2bio's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was -133.21%.

The historical rank and industry rank for Syn2bio's Return-on-Tangible-Equity or its related term are showing as below:

WAR:S2B' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -133.21   Med: -107.97   Max: -103.69
Current: -133.21

During the past 3 years, Syn2bio's highest Return-on-Tangible-Equity was -103.69%. The lowest was -133.21%. And the median was -107.97%.

WAR:S2B's Return-on-Tangible-Equity is ranked worse than
79.65% of 1199 companies
in the Biotechnology industry
Industry Median: -42.21 vs WAR:S2B: -133.21

Syn2bio  (WAR:S2B) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Syn2bio Return-on-Tangible-Equity Related Terms


Syn2bio Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Syn2bio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Return-on-Tangible-Equity Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Return-on-Tangible-Equity
-103.69 -107.97 -133.21

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Return-on-Tangible-Equity -103.69 -107.97 -133.21

WAR:S2B vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Syn2bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syn2bio Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syn2bio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Syn2bio's Return-on-Tangible-Equity falls into.


WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Return-on-Tangible-Equity Calculation

Syn2bio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-23.661/( (18.848+16.676 )/ 2 )
=-23.661/17.762
=-133.21 %

Syn2bio's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2025 )  (Q: Sep. 2024 )(Q: Sep. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2025 )  (Q: Sep. 2024 )(Q: Sep. 2025 )
=-23.661/( (18.848+16.676)/ 2 )
=-23.661/17.762
=-133.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Sep. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -133.21% mean?
Syn2bio (WAR:S2B) has a Return-on-Tangible-Equity of -133.21% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #955 out of 1199 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Syn2bio's Return-on-Tangible-Equity too high?
Syn2bio's current Return-on-Tangible-Equity is -133.21%. Based on the distribution chart, Syn2bio ranks #955 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #955 out of 1199 companies for Return-on-Tangible-Equity. This places Syn2bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syn2bio and its competitors. Syn2bio's current Return-on-Tangible-Equity is -133.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Return-on-Tangible-Equity of -133.21%. The current Return-on-Tangible-Equity is -133.21%. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Return-on-Tangible-Equity is -133.21% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price